NorthWest Biotherapeutics Inc (NWBO)

[austinmediainc]

20 Rapid-Progressor Patients: Patients with a new lesion = 1 cm. in size, or tumor growth of =25% both at a Baseline Visit and at Month 2 thereafter;
25 Indeterminate Patients: Patients with evidence of progression at the Baseline Visit (rendering them ineligible for the trial), followed by stable disease, modest progression and/or modest regression (or unclear tumor measurements), neither of which is enough to classify them as either a Rapid-Progressor or a Pseudo-Progressor;
1 Pseudo-Progressor: A patient whose Month 2 image showed resolution of most of the prior appearance of tumor growth that had been seen at the Baseline Visit.
The prognosis for Rapid Progressor patients is especially poor: their median Overall Survival is only about 8 to 10 months, according to published scientific literature, and they generally are not expected to respond much to any treatments. There is no established benchmark for Overall Survival of the Indeterminate Patients, however, they can be compared to the general population of GBM patients, for whom median Overall Survival is 14.6 months.

Interesting, the 25 indeterminate patients seem a whole lot closer to that of psPD than ePD to me. Disease progression at baseline followed by stable, modest, or regression.....

Also interesting that they highlight the fact that there is no benchmark for this new 3 rd grouping, which was missing yesterday, yet they say it can be compared to the general patient population?? SAYS WHO????? Does that not concern anybody here? Scientists, Drs, statisticians?

I know historically 2 + 2 is 4 but we get 6 and that's better!